Cytopoint

RSS

lokivetmab

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Cytopoint.It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Cytopoint.

For practical information about using Cytopoint, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.

This EPAR was last updated on 19/06/2019

Authorisation details

Product details
Name
Cytopoint
Agency product number
EMEA/V/C/003939
Active substance
lokivetmab
International non-proprietary name (INN) or common name
lokivetmab
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QD11AH91
Publication details
Marketing-authorisation holder
Zoetis Belgium SA
Revision
3
Date of issue of marketing authorisation valid throughout the European Union
25/04/2017
Contact address

Rue Laid Burniat 1
1348 Louvain-la-Neuve
Belgium

Product information

29/05/2019 Cytopoint - EMEA/V/C/003939 - IB/0006/G

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • OTHER DERMATOLOGICAL PREPARATIONS
  • agents for dermatitis excluding corticosteroids

Therapeutic indication

Treatment of clinical manifestations of atopic dermatitis in dogs.

Assessment history

How useful was this page?

Add your rating
Average
1 rating